| Description | This product is a monoclonal antibody derived from Mouse (Mus musculus), which can specifically recognize Tumor necrosis factor superfamily member 15. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Immunogen | Human recombinant TL1A |
| Isotype | IgG2a, κ |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; FC; Block |
| Application Notes | The antibody is recommended for detection of TNFSF15 by ELISA, FC, Block assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TNFSF15 |
| Alternative Name | TNFSF15; Tumor necrosis factor superfamily member 15; TL1; TL1A; VEGI; VEGI192A; tumor necrosis factor ligand superfamily member 15; TNF superfamily ligand TL1A; TNF ligand-related molecule 1; vascular endothelial cell growth inhibitor; vascular endothelial growth inhibitor-192A |
| Gene ID | 9966 |
| UniProt | O95150 |
| Research Area | Cardiovascular |
| Related Disease | Asthma, inflammatory bowel disease |
Figure 1 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in SDS-PAGE.
SDS-PAGE analysis of V3S-0522-YC1343 in reduced (Lane 1) and non-reduced (Lane 2) conditions.
The purity of V3S-0522-YC1343 was greater than 95% as determined by SDS-PAGE.
Figure 1 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in SDS-PAGE.
Figure 2 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in SEC-HPLC.
The purity of V3S-0522-YC1343 was 99.0172% as determined by SEC-HPLC.
Figure 2 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in SEC-HPLC.
Figure 3 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in Western Blot.
Western blot analysis of V3S-0522-YC1343 was performed by loading recombinant human TNFSF15 protein.
V3S-0522-YC1343 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-goat anti-mouse IgG
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 3 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in Western Blot.
Figure 4 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in ELISA.
ELISA analysis of V3S-0522-YC1343 was performed by coating with recombinant human TNFSF15 protein. Then blocked with BSA and incubated with antibody V3S-0522-YC1343. The goat anti-mouse IgG-HRP as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-TNFSF15 Neutralizing Antibody (V3S-0522-YC1343) in ELISA.
